Guidelines in major depressive disorder, and their limitations

References

• Angst J, Angst F, Gerber-Werder R, Gamma A. Suicide in 406 mood-disorder patients with and without long-term medication: a 40 to 44 years’ follow-up. Arch Suicide Res 2005; 9(3)279–300
   PubMedGoogle Scholar
• Everson S, Roberts R, Goldberg D, Kaplan G. Depressive symptoms and increased risk of stroke mortality over a 29-year period. Arch Intern Med 1998; 158(10)1133–8
   PubMed Web of Science ®Google Scholar
• Ûstün T, Ayuso-Mateos J, Chatterji S, Mathers C, Murray CJ. Global burden of depressive disorders in the year 2004. Br J Psychiatry 2004; 184: 386–92
   PubMed Web of Science ®Google Scholar
• Tylee A, Gastpar M, Lepine JP, Mendlewicz. DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee. Int Clin Psychopharmacol 1999;14((3)):139–51.
   Google Scholar
• Birnbaum H, Leong S, Greenberg P. The economics of women and depression: an employer's perspective. J Affect Disorder 2003; 74(1)15–22
   Google Scholar
• Murray C, Lopez A. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349(9063)1436–42
   PubMed Web of Science ®Google Scholar
• Murray C, Lopez A. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997; 349(9064)1498–504
   PubMed Web of Science ®Google Scholar
• Kupfer D. Long-term treatment of depression. J Clin Psychiatry 1991; 52(Suppl)28–34
   PubMed Web of Science ®Google Scholar
• Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Arch Gen Psychiatry 1984; 41: 1096–104
   PubMed Web of Science ®Google Scholar
• Prien R, Kupfer D. Continuation drug therapy for major depressive episodes: how long should it be maintained?. Am J Psychiatry 1986; 143(1)18–23
   PubMed Web of Science ®Google Scholar
• Mindham R, Howland C, Shepherd M. An evaluation of continuation therapy with tricyclic antidepressants in depressive illness. Psychol Med 1973; 3(1)5–17
   Google Scholar
• Montgomery S, Doogan D, Burnside R. The influence of different relapse criteria on the assessment of long-term efficacy of sertraline. Int Clin Psychopharmacol 1991; 6(Suppl 2)37–46
   PubMedGoogle Scholar
• Montgomery S, on behalf of the Task Force of the Collegium Internationale Neuro-Psychopharmacologicum (CINP). Impact of neuropharmacology in the 1990s – strategies for the therapy of depressive illness. Eur Neuropsychopharmacol 1993;3:153–6.
   Google Scholar
• Montgomery SA, Cowen PJ, Deakin W, et al. Thompson. Guidelines for treating depressive illness with antidepressants. A statement from the British Association for Psychopharmacology. J. Psychopharmacol 1993; 7: 19–23
   Google Scholar
• APA (American Psychiatric Association). Practice guideline for major depressive disorder in adults. Am J Psychiatry 1993;150:1–26.
   Google Scholar
• Montgomery SA, Rasmussen JG, Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993; 8: 181–8
   PubMed Web of Science ®Google Scholar
• Robert P, Montgomery SA. Citalopram in doses of 20–60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol 1995; 10(Suppl 1)29–35
   PubMedGoogle Scholar
• Montgomery S, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993; 8(3)189–95
   PubMed Web of Science ®Google Scholar
• Reimherr FW, Amsterdam JD, Quitkin FM, et al. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am J Psychiatry 1998; 155(9)1247–53
   PubMed Web of Science ®Google Scholar
• Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004; 65(1)44–9
   PubMed Web of Science ®Google Scholar
• Kennedy S, McIntyre R, Fallu A, Lam R. Pharmacotherapy to sustain the fully remitted state. J Psychiatry Neurosci 2002; 27: 269–80
   PubMed Web of Science ®Google Scholar
• MacDonald T, McMahon T, Reid I, Fenton GW, McDevitt DG. Antidepressant drug use in primary care: a record linkage study in Tayside, Scotland. Br Med J 1996; 313(7061)860–1
   Google Scholar
• Donoghue J, Tylee A. The treatment of depression: Prescribing patterns of antidepressants in primary care in the UK. Br J Psychiatry 1996; 168(2)164–8
   Google Scholar
• Simon G, VonKorff M, Wagner E, Barlow W. Patterns of antidepressant use in community practice. Gen Hosp Psychiatry 1993; 15(6)399–408
   Google Scholar
• Katon W, VonKorff M, Lin E, et al. Collaborative management to achieve treatment guidelines. Impact on depression in primary care. J Am Med Assoc 1995; 273(13)1026–31
   PubMed Web of Science ®Google Scholar
• Lin E, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995; 33(1)67–74
   PubMed Web of Science ®Google Scholar
• Angst J. The course of affective disorders. Psychopathology 1986; 19(Suppl 2)47–52
   PubMed Web of Science ®Google Scholar
• Lavori P, Dawson R, Mueller T. Causal estimation of time-varying treatment effects in observational studies: application to depressive disorder. Stat Med 1994; 13(11)1089–100
   Google Scholar
• Dawson R, Lavori PW, Coryell WH, Endicott J, Keller MB. Maintenance strategies for unipolar depression: an observational study of levels of treatment and recurrence. J Affect Disord 1998; 49(1)31–44
   Google Scholar
• Frank E, Kupfer D, Perel J, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47(12)1093–9
   Google Scholar
• Montgomery S, Dufour H, Brion S, , et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry Suppl 1988;(3):69–76.
   Google Scholar
• Klysner R, Bent-Hansen J, Hansen H, et al. Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy. Br J Psychiatry 2002; 181: 29–35
   PubMed Web of Science ®Google Scholar
• Hochstrasser B, Isaksen P, Koponen H, et al. Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy. Br J Psychiatry 2001; 178: 304–10
   PubMed Web of Science ®Google Scholar
• Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. Br Med J 2005; 330(7488)385
   PubMed Web of Science ®Google Scholar
• Isacsson G, Bergman U, Rich C. Epidemiological data suggest antidepressants reduce suicide risk among depressives. J Affect Disord 1996; 41(1)1–8
   Google Scholar
• Angst F, Stassen H, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34–38 years. J Affect Disord 2002; 68: 167–181
   PubMed Web of Science ®Google Scholar
• Olfson M, Shaffer D, Marcus S, Greenberg T. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003; 60(10)978–82
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Lecrubier Y. Is severe depression a separate indication? ECNP Consensus Meeting September 1996, Amsterdam. Eur. Neuropsychopharmacol 1999;9:259–64.
   PubMed Web of Science ®Google Scholar
• DUAG (Danish University Antidepressant Group). Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. A controlled multicenter study. Psychopharmacology (Berlin) 1986;90((1)):131–8.
   Google Scholar
• DUAG (Danish University Antidepressant Group). Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990;18, (4):289–99.
   Google Scholar
• Clerc GE, Ruimy P, Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol 1994; 9(3)139–43
   Google Scholar
• Montgomery SA, Henning F, Andersen HF. Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol 2006; 21(5)297–309
   Google Scholar
• Boulenger JP, Huusom AKT, Florea J, Bækdal T, Sarchiapone M. A comparative study of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 2006; 22(7)1331–41
   PubMed Web of Science ®Google Scholar
• Kennedy S, Andersen H, Lam R. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: A meta-analysis. J Psychiatry Neurosci 2006; 31(2)122–131
   Google Scholar
• Sánchez C, Bøgesø K, Ebert B, Reines EH, Braestrup C. Escitalopram versus citalopram: The surprising role of the R-enantiomer. Psychopharmacology (Berlin) 2004; 174: 163–76
   PubMed Web of Science ®Google Scholar
• Sánchez C. The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram. Basic Clin Pharmacol Toxicol 2006;98:91–5.
   Google Scholar
• Plenge P, Mellerup E, Laursen H. Affinity modulation of the [3H]imipramine, [3H]paroxetine and [3H]citalopram binding to the 5-HT transporter from brain and platelets. Eur J Pharmacol 1991; 206: 243–50
   PubMed Web of Science ®Google Scholar